HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine].

Abstract
A 60-year-old male patient was diagnosed as bile duct cancer with left neck and abdominal para-aortic lymph node metastasis. He was treated by combined chemotherapy of S-1 and gemcitabine(GEM). S-1 (120 mg/day) was administered 14 days followed by 14 days rest as one course. GEM (1,000 mg/m2) was administered at 8 and 15 days after the start of S-1. Combined therapy could be continued, though S-1 and GEM were reduced for neutropemia. After 5 courses of treatment, CT and MRCP revealed a partial response. S-1/GEM combined therapy was effective for inoperable biliary tract carcinoma.
AuthorsNobuhiro Akiyama, Sakura Ayata, Yuzuru Maruyama, Yoshihisa Tsukada
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 37 Issue 8 Pg. 1591-3 (Aug 2010) ISSN: 0385-0684 [Print] Japan
PMID20716894 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Drug Combinations
  • Deoxycytidine
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Gemcitabine
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bile Duct Neoplasms (diagnostic imaging, drug therapy)
  • Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use)
  • Drug Combinations
  • Fatal Outcome
  • Humans
  • Lymphatic Metastasis (diagnostic imaging)
  • Male
  • Oxonic Acid (administration & dosage, therapeutic use)
  • Tegafur (administration & dosage, therapeutic use)
  • Tomography, X-Ray Computed
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: